|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
FR2711523B1
(fr)
|
1993-10-26 |
1996-02-16 |
Transgene Sa |
Procédé de préparation d'un aérosol viral.
|
|
WO1995022618A1
(en)
|
1994-02-22 |
1995-08-24 |
Dana-Farber Cancer Institute |
Nucleic acid delivery system, method of synthesis and uses thereof
|
|
US5837520A
(en)
|
1995-03-07 |
1998-11-17 |
Canji, Inc. |
Method of purification of viral vectors
|
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
EP0944717A1
(fr)
|
1996-07-01 |
1999-09-29 |
Aventis Pharma S.A. |
Procede de production d'adenovirus recombinants
|
|
ES2278399T3
(es)
|
1996-11-20 |
2007-08-01 |
Introgen Therapeutics, Inc. |
Metodo mejorado para la produccion y purificacion de vectores adenovirales.
|
|
ATE477320T1
(de)
|
1996-12-13 |
2010-08-15 |
Schering Corp |
Methoden zur virus-reinigung
|
|
FR2763958A1
(fr)
|
1997-05-29 |
1998-12-04 |
Transgene Sa |
Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
|
|
CA2242035C
(en)
|
1997-07-01 |
2004-11-23 |
Transgene S.A. |
Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
|
|
JP2002513775A
(ja)
|
1998-05-06 |
2002-05-14 |
トランジェーヌ、ソシエテ、アノニム |
細胞の中へのポリヌクレオチドのトランスフェクションを改良する治療組成物を調製するためのヌクレアーゼインヒビターまたはインターロイキン−１０（ｉｌ−１０）の使用、および遺伝子治療に有用な組成物
|
|
JP3864610B2
(ja)
|
1998-05-21 |
2007-01-10 |
旭硝子株式会社 |
水分散型撥水撥油剤組成物およびその製造方法
|
|
EP0998945A1
(en)
|
1998-09-30 |
2000-05-10 |
Transgene S.A. |
Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
|
|
CA2356373A1
(fr)
|
1998-12-31 |
2000-07-13 |
Aventis Pharma S.A. |
Methode de separation de particules virales
|
|
EP1155120B1
(fr)
|
1999-02-22 |
2006-07-05 |
Transgene S.A. |
Procede d'obtention d'une preparation virale purifiee
|
|
JP2003518511A
(ja)
|
1999-12-28 |
2003-06-10 |
トランジェーヌ、ソシエテ、アノニム |
ポリヌクレオチドを細胞へトランスフェクションするための組成物を調製するためのリチウム（Ｌｉ＋）の使用および遺伝子治療で有用な組成物
|
|
CA2500224C
(en)
|
2002-09-25 |
2015-04-28 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
CA2519860C
(en)
|
2003-03-21 |
2018-01-16 |
Santaris Pharma A/S |
Short interfering rna (sirna) analogues
|
|
DK1648931T3
(da)
|
2003-07-21 |
2011-03-07 |
Transgene Sa |
Multifunktionelle cytokiner
|
|
WO2005073378A1
(en)
|
2004-01-30 |
2005-08-11 |
Santaris Pharma A/S |
MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
|
|
US7361468B2
(en)
*
|
2004-07-02 |
2008-04-22 |
Affymetrix, Inc. |
Methods for genotyping polymorphisms in humans
|
|
US20080213891A1
(en)
|
2004-07-21 |
2008-09-04 |
Alnylam Pharmaceuticals, Inc. |
RNAi Agents Comprising Universal Nucleobases
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
WO2007124452A2
(en)
|
2006-04-20 |
2007-11-01 |
The Regents Of The University Of California |
Methods for expressing multiple sirna and shrna from a single vector
|
|
US8680064B2
(en)
|
2008-09-15 |
2014-03-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
ShRNA gene therapy for treatment of ischemic heart disease
|
|
WO2011111072A2
(en)
|
2010-03-10 |
2011-09-15 |
Transgene Biotek Ltd. |
Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer
|
|
US9163236B2
(en)
|
2010-12-06 |
2015-10-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer
|
|
CA2863964C
(en)
*
|
2012-02-07 |
2021-10-26 |
Global Bio Therapeutics Usa, Inc. |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
|
US20130259927A1
(en)
|
2012-04-02 |
2013-10-03 |
Gradalis, Inc. |
Ewing's Sarcoma Bifunctional shRNA Design
|
|
ES2809199T3
(es)
|
2012-06-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de UBE3A-ATS
|
|
EP2872183B1
(en)
|
2012-07-11 |
2018-09-26 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated gene therapy for rpgr x-linked retinal degeneration
|
|
US10233495B2
(en)
|
2012-09-27 |
2019-03-19 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
|
KR20160089528A
(ko)
*
|
2013-12-12 |
2016-07-27 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
신경퇴행성 질환의 치료
|
|
WO2016086104A1
(en)
*
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
|
HUE067905T2
(hu)
*
|
2015-11-12 |
2024-11-28 |
Hoffmann La Roche |
Oligonukleotidok paternális UBE3A expresszió indukálására
|
|
EP3448875A4
(en)
|
2016-04-29 |
2020-04-08 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2020051417A2
(en)
|
2018-09-07 |
2020-03-12 |
The Chemours Company Fc, Llc |
Fluorine removal from antimony fluorohalide catalyst using chlorocarbons
|
|
CA3113648A1
(en)
|
2018-09-21 |
2020-03-26 |
University Of Connecticut |
Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
|